Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2363)
All Articles published online
|
Dec 28, 2007 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mandó OG. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007; 13(48): 6608-6611 [PMID: 18161937 DOI: 10.3748/wjg.v13.i48.6608] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v13/i48/6608.htm |
| Number | Citing Articles |
| 1 |
Nesrine S. El-Mezayen, Wessam F. El-Hadidy, Wessam M. El-Refaie, Th.I. Shalaby, Mahmoud M. Khattab, Aiman S. El-Khatib. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis. Journal of Controlled Release 2017; 266: 226 doi: 10.1016/j.jconrel.2017.09.035
|
| 2 |
Michael J. Mauro, Michael W. Deininger. Management of Drug Toxicities in Chronic Myeloid Leukaemia. Best Practice & Research Clinical Haematology 2009; 22(3): 409 doi: 10.1016/j.beha.2009.06.001
|
| 3 |
I. Diallo, S. B. Gning, F. Fall, B. Ndiaye, B. Fall, D. Irambona, M. Mbengue, P. S. Mbaye. Hépatotoxicité tardive à l’imatinib chez une patiente de 44 ans. Journal Africain d'Hépato-Gastroentérologie 2011; 5(3): 214 doi: 10.1007/s12157-011-0273-3
|
| 4 |
Agnieszka Karbownik, Edyta Szałek, Katarzyna Sobańska, Tomasz Grabowski, Anna Wolc, Edmund Grześkowiak. Pharmacokinetic drug-drug interaction between erlotinib and paracetamol: A potential risk for clinical practice. European Journal of Pharmaceutical Sciences 2017; 102: 55 doi: 10.1016/j.ejps.2017.02.028
|
| 5 |
Camille Houron, Marie Danielou, Olivier Mir, Bernard Fromenty, Gabriel Perlemuter, Cosmin Sebastian Voican. Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. Critical Reviews in Oncology/Hematology 2021; 157: 103127 doi: 10.1016/j.critrevonc.2020.103127
|
| 6 |
Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 2008; 17(7) doi: 10.1002/pds.1488
|
| 7 |
Simone Cunha Maradei, Angelo Maiolino, Alexandre Mello de Azevedo, Marta Colares, Luis Fernando Bouzas, Marcio Nucci. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 2009; 114(6): 1270 doi: 10.1182/blood-2009-03-212282
|
| 8 |
Mansour Tobaiqy, Nawal Helmi, Katie MacLure, Sylvia Saade. The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review. International Journal of Clinical Pharmacy 2024; 46(2): 368 doi: 10.1007/s11096-023-01671-0
|
| 9 |
Evelyn Li-Ching Chee, Adeline Yi Ling Lim, Pilar Modamio, Cecilia Fernandez-Lastra, Ignacio Segarra. Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. European Journal of Drug Metabolism and Pharmacokinetics 2016; 41(3): 309 doi: 10.1007/s13318-015-0264-7
|
| 10 |
O. Bouché, E. Scaglia, Z. Reguiai, V. Singha, H. Brixi-Benmansour, S. Lagarde. Biothérapies ciblées en cancérologie digestive : prise en charge de leurs effets secondaires. Gastroentérologie Clinique et Biologique 2009; 33(4): 306 doi: 10.1016/j.gcb.2009.02.008
|
| 11 |
Harshad Devarbhavi, Herbert L. Bonkovsky, Mark Russo, Naga Chalasani. Zakim and Boyer's Hepatology. 2018; : 844 doi: 10.1016/B978-0-323-37591-7.00056-2
|
| 12 |
N.S. AL-Sowyan. Efficacy and Safety of Folic Acid During Toxic Hepatitis Induced by Acute Overdose of Paracetamol. International Journal of Pharmacology 2009; 5(3): 208 doi: 10.3923/ijp.2009.208.214
|
| 13 |
J L Steegmann, M Baccarani, M Breccia, L F Casado, V García-Gutiérrez, A Hochhaus, D-W Kim, T D Kim, H J Khoury, P Le Coutre, J Mayer, D Milojkovic, K Porkka, D Rea, G Rosti, S Saussele, R Hehlmann, R E Clark. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30(8): 1648 doi: 10.1038/leu.2016.104
|
| 14 |
Tao Shen, Yingxia Liu, Jia Shang, Qing Xie, Jun Li, Ming Yan, Jianming Xu, Junqi Niu, Jiajun Liu, Paul B. Watkins, Guruprasad P. Aithal, Raúl J. Andrade, Xiaoguang Dou, Lvfeng Yao, Fangfang Lv, Qi Wang, Yongguo Li, Xinmin Zhou, Yuexin Zhang, Peilan Zong, Bin Wan, Zhengsheng Zou, Dongliang Yang, Yuqiang Nie, Dongliang Li, Yuya Wang, Xi’an Han, Hui Zhuang, Yimin Mao, Chengwei Chen. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. Gastroenterology 2019; 156(8): 2230 doi: 10.1053/j.gastro.2019.02.002
|
| 15 |
Zhe Wang, Lili Jiang, Xiaoyu Wang, Hang Yin, Zhen Wang, Xin Lv, Yong Liu. Cabozantinib Carries the Risk of Drug-Drug Interactions via Inhibition of UDPglucuronosyltransferase
(UGT) 1A9. Current Drug Metabolism 2022; 23(11): 912 doi: 10.2174/1389200224666221028140652
|
| 16 |
Fang Cheng, Hongxiang Wang, Weiming Li, Yu Zhang. Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective. Critical Reviews in Oncology/Hematology 2024; 195: 104258 doi: 10.1016/j.critrevonc.2024.104258
|
| 17 |
David D’Adamo. Advances in the treatment of gastrointestinal stromal tumor. Advances in Therapy 2009; 26(9) doi: 10.1007/s12325-009-0067-9
|
| 18 |
Asmaa Atteya, Aiman Ahmad, Dima Daghstani, Kamran Mushtaq, Mohamed A. Yassin. Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Cancer Control 2020; 27(1): 107327482097659 doi: 10.1177/1073274820976594
|
| 19 |
Shan Babeendran, Ariel C. Soucie. Pain Management and Palliative Care. 2015; : 189 doi: 10.1007/978-1-4939-2462-2_27
|
| 20 |
Qiang Shi, Xi Yang, Lijun Ren, William B. Mattes. Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors. Expert Opinion on Drug Metabolism & Toxicology 2020; 16(3): 217 doi: 10.1080/17425255.2020.1727886
|
| 21 |
A. Frilling, M. Malago, G. Testa, E. Schleyer, F. Grabellus, R. Kronenberger, J. Li, C.E. Broelsch. Liver Transplantation for Metastasized Extragastrointestinal Stromal Tumor: A Case Report and an Overview of Literature. Transplantation Proceedings 2010; 42(9): 3843 doi: 10.1016/j.transproceed.2010.06.016
|
| 22 |
Gabriella Mezei, Árpád Illés, Péter Batár. A krónikus myeloid leukaemia tirozin-kináz-gátló kezelésének mellékhatásai és azok gyakorlati ellátása. Orvosi Hetilap 2021; 162(30): 1198 doi: 10.1556/650.2021.32177
|
| 23 |
Damian J. Harding, Gerry MacQuillan, Rebecca Howman, Bastian de Boer, Leon Adams, Andrew Mitchell, Gary Jeffrey. Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia. Journal of Clinical Oncology 2016; 34(11): e97 doi: 10.1200/JCO.2013.50.1320
|
| 24 |
Adeline YL Lim, Ignacio Segarra, Srikumar Chakravarthi, Sufyan Akram, John P Judson. Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice. BMC Pharmacology 2010; 10(1) doi: 10.1186/1471-2210-10-14
|
| 25 |
Cyrine Haidar, Sima Jeha. Drug interactions in childhood cancer. The Lancet Oncology 2011; 12(1): 92 doi: 10.1016/S1470-2045(10)70105-4
|
| 26 |
Nelia Hernández, Fernando Bessone, Adriana Sánchez, María di Pace, Javier Brahm, Rodrigo Zapata, Ruby A. Chirino, Milagros Dávalos, Nahum Méndez-Sánchez, Marco Arrese, María Schinoni, M. Isabel Lucena, Raúl J. Andrade. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Annals of Hepatology 2014; 13(2): 231 doi: 10.1016/S1665-2681(19)30886-5
|
| 27 |
Bruno Vincenzi, Grazia Armento, Mariella Spalato Ceruso, Giovanna Catania, Mark Leakos, Daniele Santini, Giorgio Minotti, Giuseppe Tonini. Drug-induced hepatotoxicity in cancer patients - implication for treatment. Expert Opinion on Drug Safety 2016; 15(9): 1219 doi: 10.1080/14740338.2016.1194824
|
| 28 |
Cristina Martínez Pascual, Mariano Valdés Mas, Jesús Miguel de la Peña Moral, Manuel Miras López. Hepatitis fulminante por imatinib en un paciente con leucemia mieloide crónica. Medicina Clínica 2011; 137(7): 329 doi: 10.1016/j.medcli.2010.09.011
|
| 29 |
A. Bonvin, A. Mesnil, F. E. Nicolini, L. Cotte, M. Michallet, J. Descotes, T. Vial. Dasatinib-induced acute hepatitis. Leukemia & Lymphoma 2008; 49(8): 1630 doi: 10.1080/10428190802136384
|
| 30 |
Rashmi R. Shah, Joel Morganroth, Devron R. Shah. Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives. Drug Safety 2013; 36(7): 491 doi: 10.1007/s40264-013-0048-4
|
| 31 |
Feng Jin, Dan Gao, Qin Wu, Feng Liu, Yuzong Chen, Chunyan Tan, Yuyang Jiang. Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor. Bioorganic & Medicinal Chemistry 2013; 21(18): 5694 doi: 10.1016/j.bmc.2013.07.026
|
| 32 |
Amani Asnacios, Sylvie Naveau, Gabriel Perlemuter. Gastrointestinal toxicities of novel agents in cancer therapy. European Journal of Cancer 2009; 45: 332 doi: 10.1016/S0959-8049(09)70047-4
|
| 33 |
Alaa E. El-Sisi, Samia S. Sokar, Hanaa A. Ibrahim, Sally E. Abu-Risha. Enhanced anticancer activity of combined treatment of imatinib and dipyridamole in solid Ehrlich carcinoma-bearing mice. Naunyn-Schmiedeberg's Archives of Pharmacology 2020; 393(6): 1113 doi: 10.1007/s00210-019-01803-2
|
| 34 |
Jian Ren Tan, Srikumar Chakravarthi, John Paul Judson, Nagaraja Haleagrahara, Ignacio Segarra. Potential protective effect of sunitinib after administration of diclofenac: biochemical and histopathological drug–drug interaction assessment in a mouse model. Naunyn-Schmiedeberg's Archives of Pharmacology 2013; 386(7): 619 doi: 10.1007/s00210-013-0861-4
|
| 35 |
Ralph Yachoui. Early Onset Imatinib Mesylate–Induced Hepatotoxicity in a Patient With Gastrointestinal Stromal Tumors. American Journal of Therapeutics 2014; 21(5): e148 doi: 10.1097/MJT.0b013e31826fc5d1
|
| 36 |
Shubhrat Purwar, Anam Fatima, Himashree Bhattacharyya, Lakshmi Venkata Simhachalam Kutikuppala, Matei-Alexandru Cozma, Bahadar Singh Srichawla, Leah Komer, Khulud Mahmood Nurani, Mihnea-Alexandru Găman. Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms. World Journal of Hepatology 2023; 15(9): 1021-1032 doi: 10.4254/wjh.v15.i9.1021
Abstract(421) |
Core Tip(178) |
Full Article(HTML)(973)
|
Full Article with Cover (PDF)-1583K(44)
|
Full Article (Word)-332K(16)
|
Audio-1253K(3)
|
Peer-Review Report-233K(21)
|
Answering Reviewers-528K(21)
|
Full Article (PDF)-735K(68)
|
Full Article (XML)-208K(14)
|
Times Cited (1)
|
Total Visits (2608)
|
Open
|
| 37 |
Yong Liu, Jacqueline Ramírez, Mark J. Ratain. Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. British Journal of Clinical Pharmacology 2011; 71(6): 917 doi: 10.1111/j.1365-2125.2011.03911.x
|
| 38 |
Cristina Martínez Pascual, Mariano Valdés Mas, Manuel Miras López. Respuesta. Medicina Clínica 2012; 138(14): 638 doi: 10.1016/j.medcli.2011.10.005
|
| 39 |
Feng-Ru Huang, Wen-Tong Fang, Zi-Ping Cheng, Ye Shen, Dun-Jian Wang, Yong-Qing Wang, Lu-Ning Sun. Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study. Archives of Toxicology 2022; 96(4): 1075 doi: 10.1007/s00204-022-03245-x
|
| 40 |
Haochen Jiang, Ying Jin, Hao Yan, Zhifei Xu, Bo Yang, Qiaojun He, Peihua Luo. Hepatotoxicity of FDA-approved small molecule kinase inhibitors. Expert Opinion on Drug Safety 2021; 20(3): 335 doi: 10.1080/14740338.2021.1867104
|
| 41 |
Rebecca L Stone, Anil K Sood, Robert L Coleman. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. The Lancet Oncology 2010; 11(5): 465 doi: 10.1016/S1470-2045(09)70362-6
|
| 42 |
Amina Haouala, Nicolas Widmer, Michel A. Duchosal, Michael Montemurro, Thierry Buclin, Laurent A. Decosterd. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 2011; 117(8): e75 doi: 10.1182/blood-2010-07-294330
|
| 43 |
Kirsty Wai-Chung Lee, Stephen Lam Chan. Hepatotoxicity of targeted therapy for cancer. Expert Opinion on Drug Metabolism & Toxicology 2016; 12(7): 789 doi: 10.1080/17425255.2016.1190831
|
| 44 |
Susan A. Krikorian, Kanza Shamim. Adherence Issues for Oral Antineoplastics. American Journal of Lifestyle Medicine 2013; 7(3): 206 doi: 10.1177/1559827612466996
|
| 45 |
Shivakumar Chitturi, Geoffrey C. Farrell. Schiff's Diseases of the Liver. 2011; : 703 doi: 10.1002/9781119950509.ch27
|
| 46 |
Adrian Reuben, David G. Koch, William M. Lee. Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study. Hepatology 2010; 52(6): 2065 doi: 10.1002/hep.23937
|
| 47 |
Tuncer Temel, Eren Gunduz, Esmira Sadigova, Hava Uskudar Teke, Safak Meric Ozgenel, Aysegul Harmanci Ozakyol. Hepatitis B Virus Reactivation under
Treatment with Nilotinib. Euroasian Journal of Hepato-Gastroenterology 2015; 5(2): 112 doi: 10.5005/jp-journals-10018-1147
|
| 48 |
Kathryn M Field, Chris Dow, Michael Michael. Part I: Liver function in oncology: biochemistry and beyond. The Lancet Oncology 2008; 9(11): 1092 doi: 10.1016/S1470-2045(08)70279-1
|
| 49 |
Paul M. Barr, Richard J. Creger, Nathan A. Berger. Adult Acute Lymphocytic Leukemia. 2011; : 127 doi: 10.1007/978-1-60761-707-5_10
|
| 50 |
Austin C. Li, Erya Yu, Steven C. Ring, James P. Chovan. Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway. Rapid Communications in Mass Spectrometry 2014; 28(1): 123 doi: 10.1002/rcm.6758
|
| 51 |
Esther Carcelero, Helena Anglada, Montse Tuset, Natalia Creus. Interactions between oral antineoplastic agents and concomitant medication: a systematic review. Expert Opinion on Drug Safety 2013; 12(3): 403 doi: 10.1517/14740338.2013.784268
|
| 52 |
Mohammad Inamul Haq, Joanna Nixon, Adrian J Stanley. Imatinib and liver toxicity. BMJ Case Reports 2018; 11(1): e226740 doi: 10.1136/bcr-2018-226740
|
| 53 |
Isabelle Récoché, Vanessa Rousseau, Robert Bourrel, Maryse Lapeyre-Mestre, Leila Chebane, Fabien Despas, Jean-Louis Montastruc, Emmanuelle Bondon-Guitton. Drug–drug interactions with imatinib. Medicine 2016; 95(40): e5076 doi: 10.1097/MD.0000000000005076
|
| 54 |
Onder Tonyali, Ugur Coskun, Ramazan Yildiz, Tarkan Karakan, Umut Demirci, Nalan Akyurek, Mustafa Benekli, Suleyman Buyukberber. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Medical Oncology 2010; 27(3): 768 doi: 10.1007/s12032-009-9284-y
|
| 55 |
Morgane Clément, Jean-Paul Cervoni, Florian Renosi, Thierry Thévenot, Sophie Felix, Alexandre Doussot, Bruno Heyd, Éric Deconinck, Vincent Di Martino. Acute fulminant hepatitis related to the use of dasatinib: First case report. Clinics and Research in Hepatology and Gastroenterology 2022; 46(8): 102004 doi: 10.1016/j.clinre.2022.102004
|
| 56 |
Christoph Seidel, Martin Fenner, Florian Länger, Heike Bantel, Arnold Ganser, Viktor Grünwald. Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST). BMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-186
|
| 57 |
Xin Lv, Zhe Wang, Zhen Wang, Hang Yin, Yangliu Xia, Lili Jiang, Yong Liu. Drug-drug interaction potentials of tucatinib inhibition of human UDP-glucuronosyltransferases. Chemico-Biological Interactions 2023; 381: 110574 doi: 10.1016/j.cbi.2023.110574
|
| 58 |
Guilherme F. Perini, Fabio P.S. Santos, Vaneuza Funke, Jefferson Ruiz, Ben-Hur Ferraz Neto, Nelson Hamerschlak. Nilotinib post-liver transplantation for acute hepatic failure related to imatinib. Leukemia Research 2009; 33(12): e234 doi: 10.1016/j.leukres.2009.06.012
|
| 59 |
Ji Min Han, Hye Sun Gwak. Reviews on the Hepatotoxicity of Tyrosine Kinase Inhibitors. Korean Journal of Clinical Pharmacy 2019; 29(4): 223 doi: 10.24304/kjcp.2019.29.4.223
|
| 60 |
Judith A. Paice, Betty Ferrell. The management of cancer pain. CA: A Cancer Journal for Clinicians 2011; 61(3): 157 doi: 10.3322/caac.20112
|
| 61 |
Douglas A. Keller, Richard J. Brennan, Karen L. Leach. Antitargets and Drug Safety. Methods and Principles in Medicinal Chemistry 2015; : 365 doi: 10.1002/9783527673643.ch16
|
| 62 |
Ashraf Abugroun, Ahmed Chaudhary, Gabriel Rodriguez. Fatal Outcome of Imatinib in a Patient with Idiopathic Hypereosinophilic Syndrome. Case Reports in Oncological Medicine 2018; 2018: 1 doi: 10.1155/2018/6291614
|
| 63 |
Mark Ayoub, Julton Tomanguillo, Carol Faris, Nadeem Anwar, Harleen Chela, Ebubekir Daglilar. SARS-CoV-2 Infection Is an Independent Risk Factor for Decompensation in Cirrhosis Patients. Diseases 2024; 12(3): 46 doi: 10.3390/diseases12030046
|
| 64 |
Emilia Neuwirt, Giovanni Magnani, Tamara Ćiković, Svenja Wöhrle, Larissa Fischer, Anna Kostina, Stephan Flemming, Nora J. Fischenich, Benedikt S. Saller, Oliver Gorka, Steffen Renner, Claudia Agarinis, Christian N. Parker, Andreas Boettcher, Christopher J. Farady, Rebecca Kesselring, Christopher Berlin, Rolf Backofen, Marta Rodriguez-Franco, Clemens Kreutz, Marco Prinz, Martina Tholen, Thomas Reinheckel, Thomas Ott, Christina J. Groß, Philipp J. Jost, Olaf Groß. Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis. Science Signaling 2023; 16(768) doi: 10.1126/scisignal.abh1083
|
| 65 |
J. C. Kuo, S. Parakh, D. Yip. Regorafenib-induced hyperammonemic encephalopathy. Journal of Clinical Pharmacy and Therapeutics 2014; 39(4): 446 doi: 10.1111/jcpt.12160
|
| 66 |
Lucas Souto Nacif, Daniel R. Waisberg, Rafael Soares Pinheiro, Fabiana Roberto Lima, Vinicius Rocha-Santos, Wellington Andraus, Luiz Carneiro D’Albuquerque. Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report. Journal of Medical Case Reports 2018; 12(1) doi: 10.1186/s13256-018-1588-0
|
| 67 |
Franziska Paech, Jamal Bouitbir, Stephan Krähenbühl. Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis. Frontiers in Pharmacology 2017; 8 doi: 10.3389/fphar.2017.00367
|
| 68 |
Analia Azaro, Mehmet Esat Demirhan, Joann Lim, Jordi Rodon. Phase I Oncology Drug Development. 2020; : 313 doi: 10.1007/978-3-030-47682-3_18
|
| 69 |
E Jabbour, M Deininger, A Hochhaus. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011; 25(2): 201 doi: 10.1038/leu.2010.215
|
| 70 |
Agnieszka Karbownik, Edyta Szałek, Katarzyna Sobańska, Tomasz Grabowski, Agnieszka Klupczynska, Szymon Plewa, Anna Wolc, Magdalena Magiera, Joanna Porażka, Zenon J. Kokot, Edmund Grześkowiak. The concomitant use of lapatinib and paracetamol - the risk of interaction. Investigational New Drugs 2018; 36(5): 819 doi: 10.1007/s10637-018-0573-1
|